The global influenza drug market is anticipated to grow at a significant CAGR 4% during the forecast period (2022-2028). The rising prevalence of influenza is creating a global demand for flu drugs, and the increase in the number of older people who are most affected by the disease is another factor driving the demand for influenza drugs. In addition, more focus on R&D to come up with new drugs and treatments will create better opportunities for the growth of the influenza drug market.
Key developments in the market include the new FDA approvals for these drugs. For instance, in December 2019, F. Hoffmann-La Roche AG introduces Xofluza (Baloxavir marboxil) for colds and this leads to the availability of better treatment options for patients. However, the adoption of influenza drug vaccines is hampering the growth of the influenza treatment market, and the high growth potential demonstrated by emerging economies with a large population base and significant epidemiology of influenza drug infection is expected to provide profitable market opportunities during the forecast period.
Further, in October 2019, Food and Drug Administration (FDA) approved Roche’s XofluzaTM (baloxavir marboxil) new drug application (baloxavir marboxil) for dangerous cold, flu, or influenza drugs.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Global Influenza Drug Market at: https://orionmarketreports.com/request-sample/?id=93736&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By End-User
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape-Merck & Co., Inc., GlaxoSmithKline plc, Sanofi SA, Pfizer Inc., and Cipla Inc. Ltd., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
A full report of Global Influenza Drug Market is available at: https://orionmarketreports.com/global-influenza-drug-market/93736/
Global Influenza Drug Market Report by Segment
By Type
- Influenza A viruses
- Influenza B viruses
- Influenza C virus
- Influenza D viruses
By End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Global Influenza Drug Market Report by Region
North America
- US
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
About us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company name: Orion Market Reports
Contact person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
